179 related articles for article (PubMed ID: 11475345)
1. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients.
Prakash S; Walele A; Dimkovic N; Bargman J; Vas S; Oreopoulos D
Perit Dial Int; 2001; 21(3):290-5. PubMed ID: 11475345
[TBL] [Abstract][Full Text] [Related]
2. Re: Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients.
Hörl WH
Perit Dial Int; 2001; 21(5):527-8. PubMed ID: 11757843
[No Abstract] [Full Text] [Related]
3. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate.
Fishbane S; Kowalski EA
Semin Dial; 2000; 13(6):381-4. PubMed ID: 11130261
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients.
Dittrich E; Schillinger M; Sunder-Plassmann G; Hörl WH; Vychytil A
Perit Dial Int; 2002; 22(1):60-6. PubMed ID: 11929146
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.
Silverberg DS; Iaina A; Peer G; Kaplan E; Levi BA; Frank N; Steinbruch S; Blum M
Am J Kidney Dis; 1996 Feb; 27(2):234-8. PubMed ID: 8659499
[TBL] [Abstract][Full Text] [Related]
6. Tolerance and efficacy of intravenous iron saccharate for iron deficiency anemia in children and adolescents receiving long-term parenteral nutrition.
Michaud L; Guimber D; Mention K; Neuville S; Froger H; Gottrand F; Turck D
Clin Nutr; 2002 Oct; 21(5):403-7. PubMed ID: 12381338
[TBL] [Abstract][Full Text] [Related]
7. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
8. Intravenous ferric saccharate as an iron supplement in dialysis patients.
Silverberg DS; Blum M; Peer G; Kaplan E; Iaina A
Nephron; 1996; 72(3):413-7. PubMed ID: 8852489
[TBL] [Abstract][Full Text] [Related]
9. Incidence of peritonitis in chronic peritoneal dialysis patients infused with intravenous iron dextran.
Allen JR; Troidle LK; Juergensen PH; Kliger AS; Finkelstein FO
Perit Dial Int; 2000; 20(6):674-8. PubMed ID: 11216558
[TBL] [Abstract][Full Text] [Related]
10. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia.
Li H; Wang SX
Perit Dial Int; 2008; 28(2):149-54. PubMed ID: 18332450
[TBL] [Abstract][Full Text] [Related]
12. Parenteral iron use in the management of anemia in end-stage renal disease patients.
Bailie GR; Johnson CA; Mason NA
Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
[TBL] [Abstract][Full Text] [Related]
13. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients.
Park L; Uhthoff T; Tierney M; Nadler S
Am J Kidney Dis; 1998 May; 31(5):835-40. PubMed ID: 9590194
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of the efficacy of intravenous iron III-hydroxide saccharate for treating adult patients with iron deficiency anemia].
Cançado RD; Brasil SA; Noronha TG; Chiattone CS
Rev Assoc Med Bras (1992); 2005; 51(6):323-8. PubMed ID: 16444338
[TBL] [Abstract][Full Text] [Related]
15. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration.
Parkkinen J; von Bonsdorff L; Peltonen S; Grönhagen-Riska C; Rosenlöf K
Nephrol Dial Transplant; 2000 Nov; 15(11):1827-34. PubMed ID: 11071973
[TBL] [Abstract][Full Text] [Related]
16. Parenteral iron therapy: a single institution's experience over a 5-year period.
Laman CA; Silverstein SB; Rodgers GM
J Natl Compr Canc Netw; 2005 Nov; 3(6):791-5. PubMed ID: 16316614
[TBL] [Abstract][Full Text] [Related]
17. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].
Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM
Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257
[TBL] [Abstract][Full Text] [Related]
18. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion.
Kooistra MP; Kersting S; Gosriwatana I; Lu S; Nijhoff-Schutte J; Hider RC; Marx JJ
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():36-41. PubMed ID: 11886430
[TBL] [Abstract][Full Text] [Related]
19. Iron dextran treatment in peritoneal dialysis patients on erythropoietin.
Suh H; Wadhwa NK
Adv Perit Dial; 1992; 8():464-6. PubMed ID: 1361849
[TBL] [Abstract][Full Text] [Related]
20. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
